Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Bob L who wrote (376)	11/20/1999 2:24:00 PM
From: Vector1	Read Replies (1) \| Respond to of 666

Bob, IDPh can not use dosemitry in administering Y2B8 and as a result the therapeudic dose is based upon body weight and is not as precise leading to the potential for either to large or to small a dose. IMO, although it is admitedly dificult to compare studies it looks like Bex has a better side effect profile than Y2B8. One possible reason is that the gamma radiation emitted by Y tends to accumulate in the bone. V1

To: Bob L who wrote (376)	11/20/1999 2:35:00 PM
From: WTDEC	Read Replies (2) \| Respond to of 666

Bob, It seems to me that in order to make a true direct comparison you need to use both drugs in the same patient at the same time...something obviously impossible to do. Anything less than that is open to the argument of variation among patient characteristics as no two are exactly alike and even the individual patient's characteristics change over time. So, all we have to go on is what we have right now...I'm sure later studies will be made to further refine comparisons. The available facts show that in refactory cases, Bexxar shows a 70% response versus 46% on Zev. Zev gives rise to a fair number of cases of neutropenia and thrombocytopenia while Bexxar does not. I'll leave the medical theory as to why the adverse effect profile favors Bexxar to someone who knows..I do not <G>. Best regards, Walter